Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Hines Global Income Trust Announces $525M M&A Deal
Hines Global Income Trust completed three U.S. acquisitions totaling $525.3 million, including the Castings Commerce Center industrial property in Columbus ($117.0M), the 99 West Paces residential tower in Atlanta ($237.8M), and the Bishop Arts Portfolio mixed-use property in Dallas ($170.5M). These acquisitions expand the company's portfolio across high-conviction industrial, residential, and retail sectors.
Cottonwood Communities, Inc. issued and sold 216,192 shares of its Series A Convertible Preferred Stock in a private placement offering between September 18, 2026, and October 5, 2026. The company received aggregate proceeds of approximately $2.09 million from this tranche of the ongoing $200 million best-efforts private offering. The shares were sold to accredited investors at a purchase price of $10.00 per share.
Fortress Net Lease REIT issued and sold 8,864,594 common shares across multiple classes for gross proceeds of approximately $94.8 million. The shares were sold in an unregistered private placement based on the net asset value per share as of August 31, 2026.
Fortress Credit Realty Income Trust Capital Raise of $16.1M
Fortress Credit Realty Income Trust issued and sold 806,494 common shares across multiple classes for gross proceeds of approximately $16.1 million on October 1, 2026. The private placement was conducted at prices based on the net asset value per share as of August 31, 2026. Additionally, the company declared monthly distributions for all share classes payable to shareholders of record as of September 30, 2026.
Warner Bros. Discovery M&A Deal with Skydance Corporation
Warner Bros. Discovery, Inc. (WBD) completed its merger with Skydance Corporation (SKYD) on October 6, 2026, with WBD becoming a wholly owned subsidiary of SKYD. In connection with the closing, WBD repaid its existing first lien credit facilities and certain subsidiaries entered into supplemental indentures to guarantee SKYD's debt obligations.
Pyrophyte Acquisition Corp.'s sponsor, Pyrophyte Acquisition LLC, deposited $100,000 into the company's trust account to extend the deadline for completing an initial business combination. This represents the fourth monthly extension payment required to maintain the company's timeline through April 29, 2027.
ExchangeRight Income Fund's operating partnership amended its partnership agreement to create Class T Common Units. These units were specifically created to serve as consideration for the acquisition of a net-leased property to support the partnership's growth. The new units carry a fixed annual distribution rate of $1.650691 per unit and are subject to mandatory conversion into Class D Common Units upon certain events.
Nexentis Technologies amended several series of outstanding warrants to remove liability classification provisions and reclassify them as equity for accounting purposes. This action was taken specifically to help the company regain compliance with Nasdaq Listing Rule 5550(b)(1), which relates to minimum stockholders' equity requirements. The amendments do not change the exercise price, share count, or expiration dates of the warrants.
Repligen Corporation completed its acquisition of BioLife Solutions, Inc., a developer of cell processing tools for the cell and gene therapy market. Under the terms of the merger, BioLife stockholders received $11.25 in cash and 0.1442 shares of Repligen common stock for each share held. The deal expands Repligen's presence in the cell therapy workflow by adding BioLife's biopreservation media portfolio, including the CryoStor product line.
Counterparty
BioLife Solutions, Inc.
“BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies.”
Olivier Loeillot, President and Chief Executive Officer of Repligen
Biolife Solutions M&A Deal with Repligen Corporation
BioLife Solutions completed its merger with Repligen Corporation, becoming a wholly owned subsidiary of Repligen. BioLife stockholders received 0.1442 shares of Repligen common stock and $11.25 in cash for each share of BioLife common stock held. As a result of the completion, BioLife's common stock will be delisted from the Nasdaq Stock Market.
Paramount Skydance M&A Deal with Warner Bros. Discovery, Inc.
Paramount Skydance Corp (now Skydance Corporation) completed its acquisition of Warner Bros. Discovery, Inc., creating a combined global entertainment leader. In connection with the closing, the company issued $41.4 billion in senior secured notes and transferred its stock listing to the NYSE under the ticker 'SKYD'.
Bluejay Diagnostics announced baseline clinical characteristics from its SYMON-II clinical validation study, which is evaluating the Symphony IL-6 Test for mortality risk in sepsis patients. The study includes 777 evaluable patients with an 18% mortality rate, providing a diverse dataset to support the company's planned regulatory submission. The data showed that non-survivors had higher baseline illness severity, with septic shock present in 56.4% of that group.
Gulf Resources, Inc. received a formal notification from Nasdaq stating that the company has regained compliance with periodic filing requirements under Listing Rule 5250(c)(1). The company had previously been in violation of continued listing standards, but the Staff has now determined the matter is closed.
Curaleaf Holdings M&A Deal with Aurora Cannabis Inc.
Curaleaf Holdings, Inc. has filed a Notice of Variation to its existing tender offer to acquire all outstanding shares of Aurora Cannabis Inc. The amended offer increases the consideration to US$1.00 in cash plus 0.4013 Curaleaf subordinate voting shares per Aurora share and extends the expiry date to December 4, 2026.
Powercompute Wins Contract from Columbus Light and Water
PowerCompute's subsidiary entered into a new Industrial Power Contract with Columbus Light and Water to increase contracted power at its Mississippi data center from 8.5 MW to 11 MW. The agreement transitions the facility to a specific Large Data Service Rate, successfully avoiding approximately $1.5 million per megawatt in new capacity commitment charges imposed by the Tennessee Valley Authority. Additionally, the utility returned a $300,000 cash deposit to the company, which will be replaced by a utility bond.
Microbot Medical Wins Contract from Medtechnica Ltd.
Microbot Medical Inc. entered into a three-year exclusive distribution agreement with Medtechnica Ltd. to market and sell the LIBERTY Endovascular Robotic System in Israel. The company expects initial orders under the agreement to begin in the fourth quarter of 2026 following prior regulatory approval from the Israeli Ministry of Health.
Auddia Inc. cancelled its special stockholder meeting intended to vote on its proposed merger with Thramann Holdings because it failed to secure approval from a majority of outstanding shares, despite 89% of cast votes being in favor. The company plans to establish a new record date and reschedule the meeting to allow shareholders to evaluate recent strategic momentum regarding LT350's AI infrastructure platform. The merger, originally announced in February 2026, would form a new AI-native operating company called McCarthy Finney.
Option Care Health Signs $5.8B M&A Deal with Investor Group
Option Care Health has entered into a definitive agreement to be acquired by an investor group led by Clayton, Dubilier & Rice (CD&R) and McKesson Corporation for $32.05 per share in cash. The transaction reflects a total enterprise value of approximately $5.8 billion and will result in Option Care Health becoming a privately held company with CD&R as the majority owner.
ArriVent BioPharma announced that its Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant non-small cell lung cancer did not meet its primary endpoint of progression-free survival (PFS) by blinded independent central review. While the drug showed clinical benefit in secondary endpoints and a consistent safety profile, it failed to show a statistically significant improvement over chemotherapy. The company is currently evaluating the full dataset to determine the future development path for the candidate.
PDS Biotechnology announced it will host a virtual Key Opinion Leader (KOL) event on October 15, 2026, to discuss clinical outcomes from the PDS0301 Phase 2 trials. The event will focus on the metastatic colorectal cancer (mCRC) cohort, specifically patients with unresectable microsatellite stable (MSS) liver metastases, a population where immunotherapy has historically been ineffective.
Netlist Licensing Deal with Micron Technology, Inc Worth $600M
Netlist entered into a five-year patent license and settlement agreement with Micron Technology, resolving all pending legal proceedings between the companies. Micron will pay Netlist $30 million per quarter through Q3 2031, totaling $600 million, and will also purchase 10 million shares of Netlist common stock for $1 million.
Mckesson Signs $5.8B M&A Deal with Option Care Health, Inc.
McKesson Corporation and Clayton, Dubilier & Rice (CD&R) have entered into a definitive agreement to acquire Option Care Health for $32.05 per share, representing a total enterprise value of approximately $5.8 billion. Upon closing, CD&R will hold a majority stake while McKesson will hold a minority interest in the home and alternate site infusion services provider. The deal aligns with McKesson's strategy to expand access to innovative therapies in lower-cost community and home settings.
Telomir Pharmaceuticals raised approximately $5.6 million in a PIPE financing through the issuance of 4,843,300 shares of common stock at $1.16 per share. The offering included a $1.0 million investment from existing shareholder John Paul DeJoria and will be used to fund the clinical development of Telomir-Zn for triple-negative breast cancer.
Value
$5.6M
Counterparty
John Paul DeJoria
“I have always looked for opportunities that can do the greatest good for the greatest number of people, and that is part of what attracted me to Telomir. Cancer continues to take an enormous toll on patients and families, and there remains a need for new approaches that can potentially improve the way we treat this disease. Telomir is pursuing a different scientific approach, and with the Company now moving into human clinical trials, I am pleased to increase my investment and support the team as they work to determine what Telomir-Zn may be able to do for patients.”
John Paul DeJoria
“We have been very deliberate about how and when we access the capital markets. Our strategy is to raise capital around meaningful milestones, deploy it toward value-driving objectives and progressively de-risk the program, while remaining mindful of our existing shareholders. As Telomir enters clinical development, our focus is on execution: deploying this capital efficiently to advance Telomir-Zn through its Phase 1/2 clinical program, generate meaningful human data and position the Company strongly for the milestones ahead.”
Boost Run Inc.'s subsidiary entered into a material service agreement with Cohere Inc to provide dedicated GPU cloud computing infrastructure and related services. Cohere has committed to pay approximately $525.6 million over a five-year term, with infrastructure delivery expected to begin in the second quarter of 2027.
Evolution Metals & Technologies Partnership with INERGX Energy Optimisation Ltd.
Evolution Metals & Technologies Corp. (EM&T) entered into a Strategic Partnership Letter of Intent with UK-based INERGX to engineer and service energy storage systems for EM&T's planned critical materials facility in the U.S. The partnership includes a non-China supply mandate for battery components and a 10-year anticipated service term. The facility is planned to reach up to 5 GW of on-site capacity at full build-out, powered by on-site LNG generation.
OFS Capital Divestiture to New Investor for $52.3M
OFS Capital Corporation's subsidiary, SBIC I LP, admitted a third-party investor who acquired a 56.62% limited partnership interest for $52.3 million. SBIC I LP holds a significant stake in Pfanstiehl Holdings, Inc., and the proceeds will be used by the company to fund new investments and for general corporate purposes.
Regeneron Pharmaceuticals Research Collaboration with Sanofi Worth $1B
Regeneron and Sanofi entered into a Sixth Amendment to their existing Antibody LCA to co-develop and co-commercialize four new long-acting antibodies targeting IL-13, IL-4, and IL-4Rα. Sanofi will pay Regeneron an upfront payment of $1.0 billion and up to $7.0 billion in potential development, regulatory, and commercial milestones, with global profits and development costs shared equally.
Kairos Pharma reported positive interim efficacy data from its Phase 2 trial of ENV-105 (carotuximab) in combination with apalutamide for metastatic castration-resistant prostate cancer. The combination therapy demonstrated a statistically significant median progression-free survival of 17.7 months compared to 2 months for apalutamide alone (P=0.0008). Based on these results, the company has modified the trial protocol to enroll patients earlier in the disease progression and targets trial completion by Q4 2027.
Professional Diversity Network Capacity Expansion: $1.18M Investment
Professional Diversity Network's subsidiary, PDN Intelligence, committed $1.177 million to acquire and finance two NVIDIA B300 GPU systems, marking its initial entry into AI computing infrastructure. The company is leasing one system to Goodwill Labs and providing a secured loan for a second system, with operations supported by technical partner HashForest. This move represents a strategic shift from planning to execution in the company's AI infrastructure business.
Value
$1.18M
Counterparty
Goodwill Labs Inc.
Term
60 months
“We are moving from strategy to execution. By placing our initial order and committing capital toward next-generation AI computing infrastructure, we are establishing the foundation for PDN Intelligence’s operations.”
Yiran Gu, Chief Executive Officer and Chief Financial Officer
“We believe demand for advanced computing capacity will continue to create opportunities across the AI ecosystem. Our approach is to begin with disciplined infrastructure deployment, establish operating capabilities and evaluate future expansion based on market demand, utilization and economics.”
Yiran Gu, Chief Executive Officer and Chief Financial Officer
Indivior Pharmaceuticals M&A Deal with Supernus Pharmaceuticals, Inc.
Indivior Pharmaceuticals, Inc. provided a status update on its pending merger with Supernus Pharmaceuticals, Inc., specifically addressing supplemental disclosures to the joint proxy statement/prospectus. The update follows demand letters and complaints from Supernus stockholders alleging disclosure deficiencies, which the company believes are meritless but is addressing to avoid litigation risk. The special meetings for stockholders of both companies to vote on the merger are scheduled for October 15, 2026.